Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
ViaCyte was awarded a $10.1 million Strategic Partnership Award from the California Institute of Regenerative Medicine (CIRM) to support IND filing and initial clinical evaluation of an implantable cell therapy for treating diabetes. Clinical trials are projected to start in 2014.
The product, VC-01, comprises stem cell-derived pancreatic beta cell progenitors housed in a macroencapsulation device, which when implanted under the skin of a diabetes patient is expected to produce insulin and other factors that control the disease. ViaCyte has previously a number of CIRM grants to support VC-01, including a $20 million Disease Team Award in 2009.
http://www.genengnews.com/gen-news-...r-implantable-diabetes-cell-therapy/81247544/
The product, VC-01, comprises stem cell-derived pancreatic beta cell progenitors housed in a macroencapsulation device, which when implanted under the skin of a diabetes patient is expected to produce insulin and other factors that control the disease. ViaCyte has previously a number of CIRM grants to support VC-01, including a $20 million Disease Team Award in 2009.
http://www.genengnews.com/gen-news-...r-implantable-diabetes-cell-therapy/81247544/